CA2883238C — Tetracycline compounds
Assigned to Tetraphase Pharmaceuticals Inc · Expires 2021-11-23 · 4y expired
What this patent protects
The present invention is directed to a compound represented by Structural Formula: or a pharmaceutically acceptable salt thereof, where R4 is ¨(C1-C6 alkyl); and R4' is ¨(C2-C6 alkyl). Also described is a pharmaceutical composition comprising the compound, or a pharmaceuticall…
USPTO Abstract
The present invention is directed to a compound represented by Structural Formula: or a pharmaceutically acceptable salt thereof, where R4 is ¨(C1-C6 alkyl); and R4' is ¨(C2-C6 alkyl). Also described is a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, and its therapeutic use.
Drugs covered by this patent
- Xerava (ERAVACYCLINE DIHYDROCHLORIDE) · Tetraphase Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.